🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💡 68.7% of 1-year deaths after #TAVR are noncardiac. New #JACCINT analysis of #TVTRegistry shows mortality 📉 from 2012–2017, but 📈 again from 2018–2022. 🔗 ow.ly/n6Co50VROPK #Cardiology #StructuralHeart #TAVRData

🎥 Dive into #NCDAcademy’s Quick Access Content—short, introductory videos covering a variety of critical health topics like 🦠 flu, 🧬 metabolic diseases, 💻 digital health solutions, and more! Explore now: 🔗 bit.ly/41JXG6E #ACCIntl

What’s the prognostic relevance & lower limit of normal for #echofirst #GLS strain? This #JACCIMG study includes a 23K+ pt meta-analysis + 2K+ pt validation cohort. 🔗 ow.ly/IRFO50VROYm #HeartFailure Henryk Dreger #StrainImaging #CardiacFunction

🎯 #HFpEF + #Obesity + #CKD: A tough trio. #SUMMIT Trial: #Tirzepatide shows benefit, but kidney function measures raise new questions. 📈 See the nuance: 🔗 ow.ly/gjTx50VRP7t #JACC Christopher Kramer MD #CardiometabolicCare

The ACC has named Viet Le, DMSc, MPAS, PA-C, FACC, to lead its #CardioSmart patient engagement program. "I'm excited to build on my predecessors' work, providing tools for informed decisions & supporting healthy life journeys." - Viet Le DMSc PA-C FACC FAHA HF-Cert Learn more: bit.ly/4d9hBQp

In 2,853 pts w/ #Takotsubo (GEIST registry), beta-blockers were tied to ↓ follow-up mortality—but not ↓ TTS recurrence. Read the #JACCHF study: 🔗 ow.ly/VPWY50VRPgH #betablockers #TTS Sergio Raposeiras-Roubín #HeartFailure

Join us Oct 5–7 in DC for the 2025 #ACC Legislative Conference—advocate for policies that shape heart care. ✔️ Hill visits ✔️ Advocacy training ✔️ National CV community Register: ow.ly/XOEt50W570i #ACC25 #Cardiology #CVAdvocacy #HeartHealth

Deactivating #LVADs presents greater ethical challenges for clinicians than dialysis, a recent study finds. Important insights for those navigating advanced #HeartFailure care. 🔗 ow.ly/Waax50W5z3I #JACCAdvances #Cardiology

The ACC’s 🆕 “HF in a Box” toolkit is here to help clinicians elevate #HeartFailure care. 💡 Access practical tools to integrate #SGLT2 inhibitors alongside core therapies—lectures, guides, infographics & more in one place! 🔗 bit.ly/3SotOXR

📢 KSACC invites CV professionals to submit complex cases for the 12th Annual Cardiovascular Symposium 🫀 📅 Oct 25, 2025 | 📍 Olathe, KS Submit your case: ow.ly/SiXJ50WnHlZ #KSACC #Cardiology #CasePresentation

In #NSTEMI, high baseline #hsCRP was tied to pan-coronary #atherosclerosis & high-risk plaques on NIRS & #IVUS in #PROSPECTII. 🔗 ow.ly/R5hT50W5zfk #JACCINT #CardioX Ole Fröbert Gregg W. Stone MD

🏆 2025 KSACC Awards – Nominations now open! Know a Kansas clinician advancing #Cardiology or heart health? Nominate now ➡️ ow.ly/6hSN50Wpjmb Deadline: Aug 1, 2025 #KSACC #HeartHealth #CVLeadership

Plaque progression by #YesCCT & #cvPET w/ #PCSK9i? In stable pts w/ extensive non-calcified plaque, 18 mos of evolocumab Tx lowered risk plaque & microcalcification. 🔗 ow.ly/HgFp50W5zw0 #JACCIMG #cvCAD tamarappoo

Professional male bodybuilders have a significantly higher incidence of death, including a fivefold higher risk of sudden cardiac death compared with amateur bodybuilders. Learn more: bit.ly/4mBbybo #SportsCardio

Why FACC? Because you lead the way. Join a global network shaping the future of cardiology. ow.ly/qi8e50WrgXz #FACC #CVLeadership

Phase 2 PURSUIT study: AZD0780 shows promising efficacy & safety, like other #PCSK9 inhibitors—plus, it's a once-daily oral option w/ statins. Ready for larger trials. 🔗 ow.ly/xUwK50W5zEv #JACC #PCSK9i

Phase II trials are 🔑 for proving concept, but their limits in predicting Phase III outcomes matter. This #JACCBTS/HF Collaboratory paper by Dr. scottdavidsolomon, et al, explores improving HF trial go/no-go decisions. 🔗 ow.ly/Au0g50W5A8E

Why FACC? Because community matters. Stay connected. Grow stronger together. ow.ly/kyX750Wrh75 #FACC #HeartHealth

🎧 New #ACCEL Lite episode! Drs. Roger S. Blumenthal & Christina Magnussen break down a global study that moves past a North American/European lens—translating risk into years of healthy life gained. 🌍💬 Tune in: bit.ly/4kIV0N3 #cvPrev #HeartHealth

In a nationwide Danish study (2010), SCD+ incidence was higher across all age groups—but especially elevated in those w/ prior #CVD. Risk persists. More research needed. 🔗 ow.ly/XCKW50W5Akk #JACCCEP #ACCIntl